이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Applied Therapeutics 대차 대조표 상태

재무 상태 기준 확인 5/6

Applied Therapeutics 의 총 주주 지분은 $67.3M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $151.2M 및 $83.9M 입니다.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	n/a
현금	US$146.74m
주식	US$67.29m
총 부채	US$83.94m
총 자산	US$151.23m

최근 재무 상태 업데이트

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Feb 16

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Aug 13

Recent updates

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

May 28

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Feb 16

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Feb 16

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Nov 13

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Aug 11

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

May 19

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Jan 19

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Nov 11

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Aug 13

Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder

Jun 17

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

May 15

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Feb 26

How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Feb 18

Applied Therapeutics to resume galactosemia study for AT-007

Feb 02

Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling

Nov 24

Applied Therapeutics EPS misses by $0.21

Nov 12

재무 상태 분석

단기부채: APLT 의 단기 자산 ( $150.9M )이 단기 부채( $83.9M ).

장기 부채: APLT 의 단기 자산( $150.9M )이 장기 부채( $35.0K ).

부채 대 자본 내역 및 분석

부채 수준: APLT 부채가 없습니다.

부채 감소: APLT 5년 전에 부채가 없었습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: APLT 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: APLT 의 여유 현금 흐름이 역사적 비율에 따라 계속 증가하거나 감소하는 경우 충분한 현금 활주로가 있는지 판단하기에는 데이터가 부족합니다.

Applied Therapeutics 대차 대조표 상태

재무 상태 기준 확인 5/6

주요 정보

최근 재무 상태 업데이트

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Recent updates

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

Consensus revenue estimates decrease by 38%

Consensus revenue estimates decrease by 26%

Forecast to breakeven in 2026

Applied Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Applied Therapeutics, Inc. Announces Management Changes

Applied Therapeutics, Inc. Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia

Chair of the Board of Directors recently sold US$1.7m worth of stock

New major risk - Revenue and earnings growth

Applied Therapeutics, Inc. announced that it expects to receive $99.997998 million in funding from a group of investors

Applied Therapeutics, Inc. Announces Positive Interim 12-Month Results from the Ongoing Phase 3 Inspire Trial

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Applied Therapeutics, Inc. Announces Positive Results from 12-Month Interim Analysis of Govorestat (At-007) in the Ongoing Inspire Phase 3 Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Applied Therapeutics, Inc. Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy

Independent Director recently bought US$65k worth of stock

Applied Therapeutics, Inc. Appoints Les Funtleyder as Chief Financial Officer, Effective November 20, 2023

Consensus EPS estimates fall by 36%

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

New major risk - Shareholder dilution

Consensus EPS estimates fall by 13%

Consensus revenue estimates fall by 27%

New major risk - Financial position

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Consensus revenue estimates decrease by 21%

Consensus revenue estimates increase by 89%

Consensus revenue estimates increase by 1,731%

Applied Therapeutics Announces Positive Sorbitol Reduction Data from the Ongoing Phase 3 Inspire Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Price target increased by 27% to US$15.00

Insufficient new directors

Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy

Applied Therapeutics, Inc. Announces Positive Data Trend in AT-007 Action-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded Format

Price target increased to US$16.50

Applied Therapeutics, Inc.(NasdaqGM:APLT) dropped from Russell 2000 Growth Index

Applied Therapeutics Receives Orphan Medicinal Product Designation from the Ema for AT-007 for Treatment of Galactosemia

Insufficient new directors

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Applied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency at the 2022 Annual Meeting of the Peripheral Nerve Society

Price target decreased to US$12.10

Applied Therapeutics, Inc., Annual General Meeting, Jun 02, 2022

Price target decreased to US$13.63

Price target decreased to US$28.80

Applied Therapeutics, Inc. Announces Executive Changes

Applied Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Price target increased to US$39.20

Applied Therapeutics Provides Regulatory Update on Galactosemia Program

Applied Therapeutics, Inc Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency

Price target decreased to US$34.40

Price target increased to US$49.40

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Chair of the Board of Directors recently bought US$145k worth of stock

Chief Medical Officer notifies of intention to sell stock

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Chief Medical Officer exercised options and sold US$714k worth of stock

Chief Medical Officer exercised options and sold US$97k worth of stock

Price target decreased to US$44.50

Applied Therapeutics Grants Fast Track Designation by FDA for AT-007 for Galactosemia

Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder

CFO & Head of Business Development recently sold US$108k worth of stock

Chief Commercial Officer recently sold US$53k worth of stock

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Chief Medical Officer notifies of intention to sell stock

Forecast to breakeven in 2025

Independent Director exercised options to buy US$1.6m worth of stock.

New 90-day low: US$18.92

Chief Medical Officer exercised options and sold US$86k worth of stock

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Independent Director recently bought US$149k worth of stock